LAGOS, NIGERIA — Expanding access to a generic flu antiviral, Nigerian pharmaceutical firm Fidson Healthcare Plc has been chosen to manufacture a generic version of baloxavir marboxil under a landmark international licensing agreement. Granted by the United Nations-backed Medicines Patent Pool (MPP) through Swiss drugmaker Roche, the sublicence authorizes generic production and distribution across 129 low- and middle-income nations.
Announced during the United Nations General Assembly, Fidson is one of only two African manufacturers selected—alongside Uganda’s Quality Chemical Industries Limited—among 11 global companies awarded production rights.
Global Sublicense Distribution for Generic Flu Antiviral Production
The MPP selected 11 manufacturers across nine countries to establish a geographically diverse supply chain for this generic flu antiviral:
Sublicensee Company Name
Country & Region
Production Capabilities & Scope
Fidson Healthcare Plc
Nigeria (West Africa)
Regional distribution across 129 countries
Quality Chemical Industries
Uganda (East Africa)
Sub-Saharan Africa pharmaceutical supply
Laurus Labs & MSN
India (South Asia)
High-volume active ingredient supply
Desano & Guilin Pharma
China (East Asia)
Technical manufacturing & export
Biolab, Kimia Farma, Hovid
Brazil, Indonesia, Malaysia
Regional supply diversity in LATAM & ASEAN
Single-Dose Efficacy and Technical Support
Unlike older therapies that require multi-day regimens, baloxavir marboxil is administered as a single oral dose, significantly improving patient compliance. MPP Executive Director Charles Gore described the initiative as proactive pandemic preparedness, ensuring equitable access before new influenza strains emerge rather than relying on reactive emergency measures.
For local production of this generic flu antiviral, selected companies receive comprehensive support:
Technical Knowledge Transfer: Access to formulation data and reference products for bioequivalence testing.
Regulatory Pathways: Direct technical guidance to achieve NAFDAC approval and international prequalification.
National Policy Alignment: Direct alignment with Nigeria’s federal goal to produce 70 percent of essential medicines locally by 2030 under executive order tariff reliefs.
Regulatory Pathways and Industrial Policy
To commercialize this generic flu antiviral, Fidson must complete bioequivalence trials and secure regulatory approval from Nigeria’s National Agency for Food and Drug Administration and Control (NAFDAC). Establishing local production capability brings pandemic readiness directly to African soil, reducing dependence on foreign supply chains during global health crises.
Why It Matters: Securing a UN-backed global license proves Nigerian factories can meet international manufacturing benchmarks while securing local influenza treatment access.
Fidson Healthcare's Strong Performance and Expansion… Fidson Healthcare Plc has once again demonstrated its unwavering commitment to the pharmaceutical sector, announcing a profit of N4.187 billion for the financial year ending December 31, 2022. This impressive financial achievement was warmly received…
Health Emergency Initiative Receives Grant to Fight… In a significant effort to combat infant mortality and improve the well-being of vulnerable children, the Health Emergency Initiative (HEI) has received a grant for their project [1]. The grant was presented by TotalEnergies Nigeria Staff…
Fidson Healthcare Plc Partners with Chinese Firm to… In a strategic move aimed at addressing medical challenges associated with drug innovation for individuals living with the Human Immunodeficiency Virus (HIV), Fidson Healthcare Plc has announced a groundbreaking partnership with Chinese firm Jiangsu Aidea…
Diabetes in Nigeria: Why Blood Sugar Control Fails Diabetes in Nigeria does not usually fail in the clinic. Among people who reach a specialist and stay in care, control is often reasonable. It fails in the years before anyone tests you, and it…
